Patents Assigned to Cell Matrix, Inc.
-
Patent number: 7763248Abstract: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.Type: GrantFiled: May 8, 2008Date of Patent: July 27, 2010Assignee: Cell Matrix, Inc.Inventors: Jeffry D. Watkins, William D. Huse, Ying Tang, Daniel Broek, Peter Brooks
-
Patent number: 7763247Abstract: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.Type: GrantFiled: February 15, 2008Date of Patent: July 27, 2010Assignee: Cell Matrix, Inc.Inventors: Jeffry D. Watkins, William D. Huse, Ying Tang, Daniel Broek, Peter Brooks
-
Patent number: 7566770Abstract: The invention provides an antibody, or functional fragment thereof, a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.Type: GrantFiled: July 14, 2006Date of Patent: July 28, 2009Assignee: Cell-Matrix, Inc.Inventors: Jeffry D. Watkins, William D. Huse, Ying Tang, Daniel Broek, Peter Brooks
-
Publication number: 20080233133Abstract: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.Type: ApplicationFiled: February 15, 2008Publication date: September 25, 2008Applicant: Cell Matrix, Inc.Inventors: Jeffry D. Watkins, William D. Huse, Ying Tang, Daniel Broek, Peter Brooks
-
Patent number: 7390885Abstract: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.Type: GrantFiled: December 6, 2001Date of Patent: June 24, 2008Assignee: Cell Matrix, Inc.Inventors: Jeffry D. Watkins, William D. Huse, Ying Tang, Daniel Broek, Peter Brooks
-
Patent number: 7365167Abstract: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.Type: GrantFiled: November 26, 2001Date of Patent: April 29, 2008Assignee: Cell Matrix, Inc.Inventors: Jeffry D. Watkins, William D. Huse, Ying Tang, Daniel Broek, Peter Brooks
-
Publication number: 20080008707Abstract: The invention provides peptide antagonists, such as synthetic collagen peptides. The invention provides antibody antagonists, or functional fragments thereof, that preferentially bind to denatured extracellular matrix components. It additionally provides methods for using the antagonists for inhibiting angiogenesis, tumor metastasis, and other tumor developmental processes, including cell migration, cell adhesion, cell proliferation, and tumor growth and for treating angiogenesis-dependent conditions or collagen-dependent conditions. The application also provides for use of the antagonists as a vaccine for inducing an immune response, immune focusing and induction of antibody responses.Type: ApplicationFiled: June 14, 2007Publication date: January 10, 2008Applicant: Cell-Matrix, Inc.Inventors: Bruce Freimark, Dennis Van Epps, Derek Clark